System for drug-inducible expression of polynucleotides
By using the drug-induced synthetic transcription factors of human ER-derived ligand binding domain and NFκB p65 activation domain in CAR immune cells, the problems of basic expression activity and immunogenicity risks in the prior art are solved, and the problem of basic expression activity and immunogenicity risks in the prior art has been achieved. An efficient and safe drug-induced expression system in human cells.
Patent Information
- Application Number
- CN202380031011.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-01
- Filing Date
- 2023-03-30
- Publication Date
- 2024-11-15
AI Technical Summary
Existing drug-induced expression systems, especially the Tet-on system, have a basal expression activity limitation in the absence of drugs, and have significant immunogenic risks due to protein sequences derived from bacteria and viruses, leading to clinical application. Security issues.
Drug-induced synthetic transcription factors based on human ER-derived ligand binding domain, NFκB human p65 activation domain and DNA binding domain with 3 zinc finger domains are realized through the order of specific domains ( Such as tamoxifen or its derivatives) inducible expression system, reduces background expression and reduces the risk of immunogenicity.
A drug-induced expression system with low background expression and low immunogenicity risk in human cells is realized, which improves the control accuracy and safety of CAR immune cell functions, reduces side effects, and enhances therapeutic efficacy.
Smart Images

Figure CN118973608A_ABST
Abstract
Description
Field of the Invention
[0001] The present invention relates to a system for drug-inducible expression of polynucleotides in human immune cells, and in particular to a system for drug-inducible expression using a synthetic transcription factor having a defined domain order. Background of the Invention
[0003] Synthetic transcription factors composed of a DNA-binding domain (DBD), a drug-responsive ligand-binding domain (LBD), and an activation domain (AD) represent an attractive switch module for transcriptional regulation of target transgenes.
[0004] Drug-dependent transcription factors based on zinc finger-derived DBDs, mouse estrogen receptor (ER)-based LBDs, and VP16 or VP64 (both virally derived) as ADs have been described previously (Beerli et al., 2000, J. Biol. Chem. 275, 32617-32627). Although human zinc finger domains are well known for DBDs, the use of human ER-derived LBDs has been shown, for example, for Cre-recombinase (Feil et al., 1997, Biochem. Biophys. Res. Commun. 237, 752-757), and human p65 ADs have been described in combination with zinc finger-based DBDs for transcriptional regulation (Liu et al., 2001, J. Biol. Chem. 276, 11323-11334).
[0005] Adoptive transfer of CAR immune cells (e.g., CAR T cells) has demonstrated remarkable success in the treatment of hematological malignancies. However, the lack of control over the function of CAR immune cells and the subsequent excessive inflammation in patients can lead to severe side effects, especially when targeting tumor-associated antigens rather than tumor-specific antigens.
[0006] Therefore, the time, tunability and spatial control of CAR activity are crucial. In addition, other genes related to treatment have been expressed in CAR immune cells (such as cytokines), checkpoint inhibitors, etc., and strict control of the expression and activity of these genes, such as by orally available drugs, will provide the potential to improve therapeutic efficacy and limit side effects. Several methods have been taken to regulate CAR signaling and thus control activity (e.g., split CAR). In contrast, to date, CAR expression has only been regulated by adopting the Tet-on system (Sakemura, R. et al. 2016, Cancer Immunol. Res. 4, 658–68; Gu, X. et al, 2018, Int. J. Mol. Sci. 19, 1–12; Drent, E. et al. 2018, PLoS One 13, e0197349). Although effective induction rates can be obtained in the presence of doxycycline, the basal expression activity in the absence of drugs still represents an important limitation of the system. Moreover, the Tet-on system is based on protein sequences derived from bacteria and viruses and thus retains a significant risk of immunogenicity, thereby raising safety concerns for potential clinical applications.
[0007] Therefore, there is a need in the art for an improved or alternative drug-inducible system for the controlled expression of therapeutically active genes, for example, for adoptively transferred immune cells, preferably human immune cells with low immunogenic potential.
[0008] Brief description of the invention
[0009] The present inventors surprisingly found that a drug-inducible synthetic transcription factor based on a human ER-derived ligand binding domain, a human p65 activation domain of NFκB and a zinc finger-based DNA binding domain with three zinc finger domains is well suited for efficient induction in the presence of a drug (i.e., tamoxifen or its derivatives) and shows low background expression in the absence of drug only when the domains of the synthetic transcription factor are arranged in a specific order.
[0010] In contrast to well-known drug-inducible expression systems (e.g., Tet-on systems that are based at least in part on protein sequences derived from species other than humans (e.g., bacteria and viruses)), when the drug-inducible expression system as disclosed herein is used in human cells for clinical or therapeutic applications, the expression system has a reduced (or low) or diminished risk of immunogenicity in humans.
[0011] In particular, the present invention relates to a drug-inducible transcription factor that responds to tamoxifen or a tamoxifen metabolite and is characterized by a modified human ER such as LBD, a DNA binding domain comprising or consisting of three zinc finger domains and an AD derived from the human activation domain of NFκB p65, wherein C-terminal positioning of the ligand binding domain (LBD) is required to prevent background expression in the non-induced state, while achieving transcriptional activity after the addition of the drug.
[0012] Therefore, in a preferred embodiment of the present invention, the described localization of the various domains in the drug-inducible transcription factors as disclosed herein is used as a drug-inducible expression system in human cells, preferably in human immune cells (e.g., primary T cells), for expressing chimeric antigen receptors (CARs). BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 : Schematic diagram of synthetic transcription factors and switching principles. (A) Overview of inducible expression systems with the possibility to control any target transgene. Synthetic transcription factors consist of a DNA binding domain, a ligand-inducible domain, and an activation domain. Transcription of the transgene is initiated when the synthetic transcription factor binds to its response element upstream of the minimal promoter. (B) Overview of anti-CD20 CAR induction in T cells. The "on" and "off" states of inducible anti-CD20 CAR T cells can be controlled by administering an inducer drug.
[0015] Figure 2 : Induction of anti-CD20 CAR expression in primary T cells.
[0016] T cells were transduced with an inducible switch system and a constitutively expressed anti-CD20 CAR ("direct CAR"), the inducible switch system comprising a synthetic transcription factor consisting of an N1 zinc finger protein in different directions of each domain, a ligand binding domain of the human estrogen receptor, and an activation domain derived from NFκB p65. T cells were cultured for 40 hours in the presence of 0-250nM 4-OHT and analyzed by flow cytometry for anti-CD20 CAR expression using anti-CD20 CAR detection reagent-PE. The frequency of anti-CD20 CAR+ induced T cells (left figure) and the mean fluorescence intensity (MFI) of anti-CD20 CAR expression (right figure) were determined and normalized to the expression of the transduction marker LNGFR.
[0017] Figure 3: Cytotoxic activity of inducible anti-CD20 CAR T cells in co-culture with GFP+CD20+Mel526. Inducible anti-CD20 CAR T cells were co-cultured with GFP+CD20+526-MEL at an E:T ratio of 1:1 in the absence or presence of 100 nM 4-OHT added at the beginning of the assay. Using a live cell imaging device The growth of tumor cells was monitored at 2 h intervals over a period of 100 h. Untransduced T cells were used as negative controls, while a conventional constitutively expressed anti-CD20 CAR ("direct CAR") represented a positive control.
[0018] Figure 4 : Cytokine secretion of inducible anti-CD20 CAR T cells in co-culture with GFP+CD20+Mel526. In the absence or presence of 100nM4-OHT added at the beginning of the assay, inducible anti-CD20 CAR T cells were co-cultured with GFP+CD20+526-Mel at an E:T ratio of 1:1. At 40h after the start of the assay, the concentrations of human IFN-γ (left) and IL-2 (right) in the supernatant of the co-culture were measured using the MACSPlex cytokine kit.
[0019] Figure 5 : Cytotoxic activity of inducible anti-CD20 CAR T cells in vivo.
[0020] On day 7, NSG were injected via tail vein. TM Mice were inoculated with 4×10 5 RajiffLuc cells. On day 0, after randomization, mice were treated with untransduced, inducible, or conventional constitutively expressed ("direct") anti-CD20 CAR T cells. Starting on day -1, tamoxifen was administered daily to the designated groups by ip injection. For individual mice, tumor burden was regularly determined by in vivo BLI and expressed as photon flux [photons / second] over time.
[0021] Figure 6:The positioning of the activation domain within the synthetic transcription factor determines the background expression in the non-induced state and transcriptional output. T cells were transduced with synthetic transcription factors containing zinc finger proteins (N1) of different arrangements, ligand binding domains of estrogen receptors (ER), and activation domains (p65). The expression of anti-CD20 CAR was induced by adding 0-250nM 4-OHT to the cell culture. 40h after induction, the expression of anti-CD20 CAR was analyzed by flow cytometry and normalized to the expression of transduction marker LNGFR. The frequency of anti-CD20CAR+T cells (left figure) and the MFI of anti-CD20CAR+T cells (right figure) were plotted.
[0022] Figure 7 :The selection of activation domains within synthetic transcription factors determines background expression in the non-induced state and transcriptional output. T cells were transduced with synthetic transcription factors containing zinc finger proteins (N1) with different arrangements, ligand binding domains of estrogen receptors (ER), and different activation domains (NFκB p65 (aa361-551), NFκB p65 (aa288-548), fusion proteins of NFκB p65 and HSF-1, or VP64). The expression of anti-CD20 CAR was induced by adding 0-250nM 4-OHT to cell culture. 40h after induction, the expression of anti-CD20 CAR was analyzed by flow cytometry and normalized to the expression of transduction marker LNGFR. The frequency of anti-CD20CAR+T cells (left figure) and the MFI of anti-CD20 CAR+T cells (right figure) were plotted. DETAILED DESCRIPTION OF THE INVENTION
[0024] In a first aspect, the present invention provides a system for drug-inducible expression of a polynucleotide (in human immune cells), comprising
[0025] a) a first nucleic acid sequence comprising a first promoter inducible by the drug, wherein the first promoter is operably linked to the polynucleotide, wherein the first promoter comprises a binding site for a DNA binding domain, wherein the binding site comprises at least one response element recognized (bound) by the DNA binding domain (DBD), and
[0026] b) a second nucleic acid sequence comprising a second promoter, wherein the second promoter is operably linked to a nucleic acid sequence encoding a synthetic transcription factor, wherein the synthetic transcription factor comprises
[0027] i) an activation domain (AD), wherein the AD comprises the p65 activation domain of the human transcription factor NFκB or a functional variant thereof,
[0028] ii) the DNA binding domain (DBD), wherein the DBD comprises or consists of three zinc finger domains,
[0029] iii) a ligand binding domain (LBD), wherein the LBD is a modified human estrogen receptor capable of binding the drug, wherein the drug is tamoxifen or a metabolite of tamoxifen,
[0030] c) the drug.
[0031] The DNA binding domain (DBD) can be a polypeptide having three zinc finger domains. Each zinc finger domain can contain a recognition sequence, which determines the specificity of the domain to the response element of the DNA binding site.
[0032] The recognition sequence can be, for example, SEQ ID NO: 1 (recognition sequence sites -2 to 6 of the fingers that recognize the target site GAA (relative to the start of the α-helix)) and / or SEQ ID NO: 2 (recognition sequence sites -2 to 6 of the fingers that recognize the target site GTA (relative to the start of the α-helix)) and / or SEQ ID NO: 3 (recognition sequence sites -2 to 6 of the fingers that recognize the target site GGG (relative to the start of the α-helix)).
[0033] The zinc finger domain recognizes the target site 3 bp in length. The amino acids at positions -1, 2, 3, and 6 relative to the start of the α-helix of the zinc finger domain are responsible for DNA recognition.
[0034] The consensus zinc finger framework sequence derived from native and mutant forms of Sp1 zinc fingers can be SEQ ID NO:4.
[0035] The zinc finger protein may be an N1 zinc finger protein (N1 ZFP or N1).
[0036] The N1 may comprise the sequence of SEQ ID NO:5.
[0037] The corresponding response element for N1 may be SEQ ID NO:6.
[0038] The binding site may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9 or more response elements that can be recognized (bound) by the DNA binding domain (DBD).
[0039] If the zinc finger protein is an N1 ZFP, the binding site may comprise five response elements, wherein each response element may comprise two direct repeats of the recognition motif SEQ ID NO: 7 separated by 3 or 4 base pairs (bps).
[0040] The polynucleotide may be a polynucleotide encoding a peptide or a polypeptide or a protein.
[0041] The protein may be, for example, a chimeric antigen receptor (CAR), a cytokine, or an antibody or a fragment thereof, such as a Fab.
[0042] The polynucleotide may be a polynucleotide encoding a therapeutically active protein.
[0043] The polynucleotide may be a polynucleotide miRNA, siRNA or shRNA.
[0044] The first promoter may be an inducible promoter, wherein the first promoter may be inducible by a drug as disclosed herein, and wherein the first promoter may comprise a binding site for a DNA binding domain, wherein the binding site comprises at least one response element recognized (bound) by a DNA binding domain (DBD).
[0045] The second promoter may be a constitutive promoter.
[0046] The second promoter may be, for example, the EF-1α promoter or any other constitutive promoter that drives constitutive expression in immune cells, such as MSCV, PGK-1, UBC, CMV, CAGG, SV40, or a pan-hematopoietic promoter, such as vav.
[0047] The second promoter may be EF1α.
[0048] The drug may be tamoxifen or a metabolite of tamoxifen, or an analog of tamoxifen.
[0049] The metabolite of tamoxifen or the analog of tamoxifen may be 4-hydroxytamoxifen (4-OHT) or endoxifen.
[0050] The p65 activation domain of human transcription factor NFκB may be, for example, the entire sequence of SEQ ID NO: 8, or aa361 to aa551 of SEQ ID NO: 8, or aa288 to aa548 of SEQ ID NO: 8, or aa 360 to aa551 of SEQ ID NO: 8.
[0051] The modified human estrogen receptor may comprise modifications that result in loss of responsiveness to a natural ligand (ie, human estrogen) but not to a synthetic ligand (ie, a drug such as a metabolite of tamoxifen, for example, 4-hydroxytamoxifen or endoxifen).
[0052] The modified human estrogen receptor, wherein compared with the wild-type amino acid sequence of the human estrogen receptor, the modified human estrogen receptor may comprise amino acid substitutions G400V, M543A, L544A or G400V, L540A, M543A.
[0053] An unmodified portion of human ER that can be used in a synthetic transcription factor as disclosed herein can comprise SEQ ID NO: 9 (human ER aa282 to aa595).
[0054] The modified human estrogen receptor, wherein the modified human estrogen receptor may comprise SEQ ID NO: 10 (human ER (G400V, L540A, M543A)) or SEQ ID NO: 11 (human ER (G400V, M543A, L544A)) or SEQ ID NO: 12 (human ER (G400V / L539A / L540A)).
[0055] A system as disclosed herein, wherein the polynucleotide encodes a chimeric antigen receptor (CAR) or an exogenous T cell receptor (TCR).
[0056] The CAR may include
[0057] i) an antigen-binding domain that is specific for an antigen expressed on the surface of a target cell or is specific for a soluble antigen or is specific for a tag of a tagged polypeptide, wherein the tagged polypeptide may be specific for an antigen on the surface of a target cell,
[0058] ii) transmembrane domain,
[0059] iii) Intracellular signaling domain.
[0060] A system as disclosed herein, wherein the polynucleotide encodes a chimeric antigen receptor (CAR), wherein the CAR is expressed in a human immune cell (e.g., a T cell, e.g., a primary T cell or a NK cell).
[0061] A system as disclosed herein, wherein the first nucleic acid sequence and the second nucleic acid sequence are on different nucleic acid sequences, or wherein the first nucleic acid sequence and the second nucleic acid sequence are on one nucleic acid sequence.
[0062] The one nucleic acid sequence may be a vector, such as a retroviral vector. The retroviral vector may be a lentiviral vector.
[0063] The vector, such as a retroviral vector or a lentiviral vector, may comprise the first nucleic acid sequence in a 3' to 5' orientation (compared to the second nucleic acid sequence). This is to avoid read-through and resulting background transcription in the absence of the drug.
[0064] In a further aspect, the present invention provides a composition comprising
[0065] A) Human immune cells, including
[0066] a) a first nucleic acid sequence comprising a first promoter inducible by a drug, wherein the first promoter is operably linked to the polynucleotide, wherein the first promoter comprises a binding site for a DNA binding domain, wherein the binding site comprises at least one response element recognized (bound) by the DNA binding domain (DBD), and
[0067] b) a second nucleic acid sequence comprising a second promoter, wherein the second promoter is operably linked to a nucleic acid sequence encoding a synthetic transcription factor, wherein the synthetic transcription factor comprises
[0068] i) an activation domain (AD), wherein the AD comprises the p65 activation domain of the human transcription factor NFκB or a functional variant thereof,
[0069] ii) a DNA binding domain (DBD), wherein the DBD comprises or consists of three zinc finger domains,
[0070] iii) a ligand binding domain (LBD), wherein the LBD is a modified human estrogen receptor capable of binding the drug, and wherein the ligand binding domain (LBD) is located at the C-terminus of the synthetic transcription factor,
[0071] B) the drug, wherein the drug is tamoxifen or a metabolite of tamoxifen.
[0072] The human immune cells may be T cells or NK cells.
[0073] The polynucleotides may be polynucleotides encoding CAR. The CAR may be specific to a tumor antigen or a tumor-associated antigen (TAA) expressed, for example, on the cell surface of a tumor (target) cell, or may be a soluble antigen.
[0074] In another aspect, the present invention provides a composition for treating a disease (of a subject), comprising:
[0075] A) Human immune cells, including
[0076] a) a first nucleic acid sequence comprising a first promoter inducible by a drug, wherein the first promoter is operably linked to a polynucleotide (to be expressed), wherein the first promoter comprises a binding site for a DNA binding domain, wherein the binding site comprises at least one response element recognized by the DNA binding domain (DBD), and
[0077] b) a second nucleic acid sequence comprising a second promoter, wherein the second promoter is operably linked to a nucleic acid sequence encoding a synthetic transcription factor, wherein the synthetic transcription factor comprises
[0078] i) an activation domain (AD), wherein the AD comprises the p65 activation domain of the human transcription factor NFκB or a functional variant thereof,
[0079] ii) a DNA binding domain (DBD), wherein the DBD comprises or consists of at least three zinc finger domains,
[0080] iii) a ligand binding domain (LBD), wherein the LBD is a modified human estrogen receptor capable of binding the drug, and wherein the ligand binding domain (LBD) is located at the C-terminus of the synthetic transcription factor,
[0081] B) the drug, wherein the drug is tamoxifen or a metabolite of tamoxifen.
[0082] The disease may be cancer, an autoimmune disease or an infectious disease.
[0083] In another aspect, the present invention provides a combination of a pharmaceutical composition comprising a first composition and a second composition,
[0084] The first composition comprises human immune cells, comprising
[0085] a) a first nucleic acid sequence comprising a first promoter inducible by a drug, wherein the first promoter is operably linked to a polynucleotide (to be expressed), wherein the first promoter comprises a binding site for a DNA binding domain, wherein the binding site comprises at least one response element recognized by the DNA binding domain (DBD), and
[0086] b) a second nucleic acid sequence comprising a second promoter, wherein the second promoter is operably linked to a nucleic acid sequence encoding a synthetic transcription factor, wherein the synthetic transcription factor comprises
[0087] i) an activation domain (AD), wherein the AD comprises the p65 activation domain of the human transcription factor NFκB or a functional variant thereof,
[0088] ii) a DNA binding domain (DBD), wherein the DBD comprises or consists of three zinc finger domains,
[0089] iii) a ligand binding domain (LBD), wherein the LBD is a modified human estrogen receptor capable of binding the drug, and wherein the ligand binding domain (LBD) is located at the C-terminus of the synthetic transcription factor, and optionally
[0090] c) a pharmaceutically acceptable carrier, and
[0091] B) the drug, wherein the drug is tamoxifen or a metabolite of tamoxifen, and optionally a pharmaceutically acceptable carrier.
[0092] Pharmaceutically acceptable carriers, diluents or excipients may include buffers, such as neutral buffered saline, phosphate buffered saline, etc.; carbohydrates such as glucose, mannose, sucrose or dextran, mannitol; proteins; polypeptides or amino acids, such as glycine; antioxidants; chelating agents, such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives.
[0093] In a further aspect, the present invention provides an in vivo method for treating a disease in a subject, the method comprising:
[0094] A) administering human immune cells to the subject, comprising
[0095] a) a first nucleic acid sequence comprising a first promoter inducible by a drug, wherein the first promoter is operably linked to a polynucleotide (to be expressed), wherein the first promoter comprises a binding site for a DNA binding domain, wherein the binding site comprises at least one response element recognized by the DNA binding domain (DBD), and
[0096] b) a second nucleic acid sequence comprising a second promoter, wherein the second promoter is operably linked to a nucleic acid sequence encoding a synthetic transcription factor, wherein the synthetic transcription factor comprises
[0097] i) an activation domain (AD), wherein the AD comprises the p65 activation domain of the human transcription factor NFκB or a functional variant thereof,
[0098] ii) a DNA binding domain (DBD), wherein the DBD comprises or consists of at least three zinc finger domains, and
[0099] iii) a ligand binding domain (LBD), wherein the LBD is a mutant human estrogen receptor capable of binding to the drug, and wherein the ligand binding domain (LBD) is located at the C-terminus of the synthetic transcription factor,
[0100] b) administering the drug to the subject, wherein the drug is tamoxifen or a metabolite of tamoxifen.
[0101] In another aspect, the present invention provides a kit for drug-inducible expression of a polynucleotide (in human immune cells), comprising
[0102] a) a first nucleic acid sequence comprising the drug-inducible first promoter, wherein the first promoter is operably linked to the polynucleotide, wherein the first promoter comprises a binding site for a DNA binding domain, wherein the binding site comprises at least one response element recognized (bound) by the DNA binding domain (DBD), and
[0103] b) a second nucleic acid sequence comprising a second promoter, wherein the second promoter is operably linked to a nucleic acid sequence encoding a synthetic transcription factor, wherein the synthetic transcription factor comprises
[0104] i) an activation domain (AD), wherein the AD comprises the p65 activation domain of the human transcription factor NFκB or a functional variant thereof,
[0105] ii) the DNA binding domain (DBD), wherein the DBD comprises or consists of three zinc finger domains,
[0106] iii) a ligand binding domain (LBD), wherein the LBD is a modified human estrogen receptor capable of binding the drug, and wherein the ligand binding domain (LBD) is located at the C-terminus of the synthetic transcription factor,
[0107] c) the drug, wherein the drug is tamoxifen or a metabolite of tamoxifen.
[0108] All definitions, features and embodiments defined herein for the first aspect of the invention as disclosed herein also apply mutatis mutandis in the context of the other aspects of the invention as disclosed herein.
[0109] definition
[0110] Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0111] As used herein, the terms "comprising" or "including" are used to refer to compositions, methods, and their respective components, which are essential to the method or composition, but are open to including unspecified elements, whether essential or not.
[0112] In the context of a system for drug-inducible expression of a polypeptide (in a cell), the term "system" may refer to a combination of a nucleic acid (nucleic acid sequence) present in, for example, a human immune cell and a drug as disclosed herein.
[0113] Typically, CAR may include an extracellular domain (extracellular portion) containing an antigen binding domain, a transmembrane domain, and a cytoplasmic signaling domain (intracellular signaling domain). The extracellular domain may be connected to the transmembrane domain by a linker or a spacer. The extracellular domain may also include a signal peptide. In some embodiments of the present invention, the antigen binding domain of CAR binds to a label or hapten coupled to a polypeptide ("haptenized" or "tagged" polypeptide), wherein the polypeptide may bind to a disease-associated antigen, such as a tumor-associated antigen (TAA) that may be expressed on the surface of a cancer cell.
[0114] Such CAR may be referred to as "anti-tag" CAR or "adapter CAR" or "universal CAR", such as disclosed in US9233125B2.
[0115] A hapten or label can be directly or indirectly coupled to a polypeptide (tagged polypeptide), wherein the polypeptide can be bound to the disease-associated antigen expressed on the (cell) surface of the target. The label can be, for example, a dextran or a hapten, such as biotin or fluorescein isothiocyanate (FITC) or phycoerythrin (PE) or thiamine, but the label can also be a peptide sequence, such as a chemical or recombinant coupling to the polypeptide portion of the tagged polypeptide. The label can also be streptavidin. The label portion of the tagged polypeptide is limited only to molecules that can be recognized and specifically bound by an antigen binding domain that is specific to the label of CAR. For example, when the label is FITC (fluorescein isothiocyanate), the label binding domain can constitute an anti-FITC scFv. Alternatively, when the label is biotin or PE (phycoerythrin), the label binding domain can constitute an anti-biotin scFv or an anti-PE scFv, respectively.
[0116] "Signal peptide" refers to a peptide sequence that directs the transport and localization of a protein within a cell, for example, transport and localization to a certain organelle (eg, endoplasmic reticulum) and / or the cell surface.
[0117] Typically, "antigen binding domain" refers to the region of a CAR that specifically binds to an antigen (e.g., a tumor-associated antigen (TAA) or a tumor-specific antigen (TSA)). The CAR of the present invention may include one or more antigen binding domains (e.g., a tandem CAR). Typically, the targeting region on the CAR is extracellular. The antigen binding domain may include an antibody or its antigen binding fragment. The antigen binding domain may include, for example, a full-length heavy chain, a Fab fragment, a single-chain Fv (scFv) fragment, a bivalent single-chain antibody, or a double antibody. Any molecule that specifically binds to a given antigen, such as an affibody or a ligand binding domain from a naturally occurring receptor, can be used as an antigen binding domain. Typically, the antigen binding domain is an scFv. Typically, in an scFv, the variable regions of the immunoglobulin heavy chain and light chain are fused by a flexible linker to form an scFv. Such a linker may be, for example, a "(G4 / S)3-linker".
[0118] In some cases, it is beneficial for the antigen binding domain to be derived from the same species in which the CAR will be used. For example, when it is planned to be used therapeutically in humans, it may be beneficial for the antigen binding domain of the CAR to comprise a human or humanized antibody or antigen binding fragment thereof. Human or humanized antibodies or antigen binding fragments thereof can be prepared by a variety of methods well known in the art.
[0119] As used herein, "spacer" or "hinge" refers to a hydrophilic region between an antigen binding domain and a transmembrane domain. The CAR of the present invention may include an extracellular spacer domain, but such a spacer may also be omitted. The spacer may include, for example, an Fc fragment of an antibody or a fragment thereof, a hinge region of an antibody or a fragment thereof, a CH2 or CH3 region of an antibody, an auxiliary protein, an artificial spacer sequence, or a combination thereof. A notable example of a spacer is a CD8α hinge.
[0120] The transmembrane domain of CAR can be derived from any desired natural or synthetic source of such domain. When the source is natural, the domain can be derived from any membrane-bound or transmembrane protein. The transmembrane domain can be derived from, for example, CD8α or CD28. When the key signaling and antigen recognition modules (domains) are on two (or even more) polypeptides, CAR can have two (or more) transmembrane domains. Due to the small molecule-dependent heterodimerization domains in each polypeptide of CAR, splitting the key signaling and antigen recognition modules enables small molecule-dependent, titratable and reversible control of CAR cell expression (e.g., WO2014127261A1). .
[0121] The cytoplasmic signaling domain of CAR (intracellular signaling domain or activation intracellular domain (endodomain)) is responsible for the activation of at least one normal effector function of the immune cell expressing CAR, if the corresponding CAR is an activating CAR (generally, CAR as described herein refers to an activating CAR, otherwise it is explicitly indicated as an inhibitory CAR (iCAR)). "Effector function" refers to a specialized function of a cell, for example, in T cells, the effector function can be a cytolytic activity or an auxiliary activity, including the secretion of cytokines. The intracellular signaling domain refers to a part of a protein that transduces an effector function signal and instructs the cell expressing CAR to perform a specialized function. The intracellular signaling domain may include any complete, mutated or truncated portion of the intracellular signaling domain of a given protein that is sufficient to transduce a signal that initiates or blocks an immune cell effector function.
[0122] Notable examples of intracellular signaling domains for CARs include the cytoplasmic signaling sequences of the T cell receptor (TCR) and co-receptors, which initiate signal transduction following antigen receptor engagement.
[0123] In general, T cell activation can be mediated by two different categories of cytoplasmic signaling sequences, firstly those that initiate antigen-dependent primary activation through TCR (primary cytoplasmic signaling sequences, primary cytoplasmic signaling domains), and secondly those that act in an antigen-independent manner to provide secondary or costimulatory signals (secondary cytoplasmic signaling sequences, costimulatory signaling domains). Therefore, the intracellular signaling domain of a CAR may include one or more primary cytoplasmic signaling domains and / or one or more secondary cytoplasmic signaling domains.
[0124] The primary cytoplasmic signaling domain that acts in a stimulatory manner may contain an ITAM (immunoreceptor tyrosine-based activation motif).
[0125] Examples of primary cytoplasmic signaling domains containing ITAMs that are frequently used in CARs are those derived from TCRζ (CD3ζ), FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b, and CD66d. The most notable is the sequence derived from CD3ζ.
[0126] The cytoplasmic domain of CAR can be designed to include the CD3ζ signaling domain itself or in combination with any other desired cytoplasmic domain. The cytoplasmic domain of CAR can include CD3ζ chain portion and costimulatory signaling region (domain). The costimulatory signaling region refers to a part of the CAR comprising the intracellular domain of the costimulatory molecule. Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands required for the effective response of lymphocytes to antigens. Examples of costimulatory molecules are CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3.
[0127] The cytoplasmic signaling sequences within the cytoplasmic signaling portion of the CAR can be connected to each other in a random or specified order with or without a linker. A short oligopeptide or polypeptide linker, preferably 2 to 10 amino acids in length, can form the connection. A notable linker is a glycine-serine doublet.
[0128] As an example, the cytoplasmic domain can include the signaling domain of CD3 zeta and the signaling domain of CD28. In another example, the cytoplasmic domain can include the signaling domain of CD3 zeta and the signaling domain of CD137. In a further example, the cytoplasmic domain can include the signaling domain of CD3 zeta, the signaling domain of CD28, and the signaling domain of CD137.
[0129] As previously mentioned, the extracellular portion or transmembrane domain or cytoplasmic domain of the CAR may also contain a heterodimerization domain for the purpose of splitting the key signaling and antigen recognition modules of the CAR.
[0130] CAR can be further modified to include one or more operating elements at the nucleic acid level encoding CAR to eliminate immune cells expressing CAR by suicide switch.Suicide switch can include, for example, a signal transduction cascade that induces apoptosis or a drug that induces cell death.In one embodiment, the nucleic acid expressing and encoding CAR can be further modified to express enzymes, such as thymidine kinase (TK) or cytosine deaminase (CD).CAR can also be part of a gene expression system that allows controlled expression of CAR in immune cells.Such a gene expression system can be an inducible gene expression system, and wherein when an inducer is applied to a cell transduced by the inducible gene expression system, the gene expression system is induced and the CAR is expressed on the surface of the transduced cell.
[0131] In some embodiments, the intracellular domain can contain either the primary cytoplasmic signaling domain or the co-stimulatory region, but not both.
[0132] In some embodiments of the invention, the CAR can be a "SUPRA" (split, universal and programmable) CAR, in which the "zipCAR" domain can connect the intracellular co-stimulatory domain and the extracellular leucine zipper (WO2017 / 091546). The zipper can be targeted with a complementary zipper fused to the scFv region, for example, to make the SUPRA CAR T cells tumor-specific. This method is particularly useful for generating universal CAR T cells for various tumors; aptamer molecules can be designed for tumor specificity and will provide options for changing specificity after adoptive transfer, which is critical for selection pressure and antigen escape situations.
[0133] The CAR of the present invention can be designed to contain any portion or part of the above-mentioned domains as described herein in any order and / or combination, thereby producing a functional CAR, i.e., a CAR that mediates an immune effector response of an immune effector cell expressing a CAR as disclosed herein.
[0134] As used herein, the term "tagged polypeptide" refers to a polypeptide having at least one additional component (i.e., a tag) directly or indirectly bound thereto. As used herein, a tagged polypeptide is capable of binding to an antigen expressed on a target cell. The polypeptide may be an antibody or antigen-binding fragment thereof that binds to an antigen expressed on the surface of a target cell (e.g., a tumor-associated antigen on a cancer cell). The polypeptide of the tagged polypeptide may alternatively be a cytokine or growth factor or another soluble polypeptide capable of binding to an antigen of a target cell.
[0135] As used herein, the terms "aptamer" or "aptamer molecule" or "tagged polypeptide" are used interchangeably.
[0136] The tag can be, for example, a hapten or a dextran, and the hapten or dextran can be bound by an antigen binding domain of a polypeptide (eg, a CAR) comprising an antigen binding domain specific for the tag.
[0137] Haptens such as FITC, biotin, PE, streptavidin or dextran are small molecules that elicit an immune response only when attached to a large carrier (e.g., a protein); a carrier may be one that also does not elicit an immune response by itself. Once the body has produced antibodies to the hapten-carrier adduct, small molecule haptens may also be able to bind antibodies, but they generally do not elicit an immune response; generally only hapten-carrier adducts can do so.
[0138] However, the tag can also be a peptide sequence that is, for example, chemically or recombinantly coupled to a polypeptide portion of a tagged polypeptide. The peptide can be selected from a group consisting of a c-Myc tag, a Strep-tag, a Flag-tag, and a polyhistidine-tag. The tag can also be streptavidin. The tag portion of the tagged polypeptide is limited only to molecules that can be recognized and specifically bound by an antigen binding domain that is specific to the CAR tag. For example, when the tag is FITC (fluorescein isothiocyanate), the tag-binding domain can constitute an anti-FITC scFv. Alternatively, when the tag is biotin or PE (phycoerythrin), the tag-binding domain can constitute an anti-biotin scFv or an anti-PE scFv.
[0139] As used herein, "T cell receptor" or "TCR" refers to an antigen recognition molecule present on the surface of a T cell. During normal T cell development, each of the four TCR genes α, β, γ, β can be rearranged, resulting in highly diverse TCR proteins.
[0140] As used herein, the term "antibody" is used in the broadest sense to cover various forms of antibody structures, including but not limited to monoclonal and polyclonal antibodies (including full-length antibodies) that specifically recognize (i.e., bind) antigens, multispecific antibodies (e.g., bispecific antibodies), antibody fragments (i.e., antigen-binding fragments of antibodies), immunoadhesins, and antibody-immunoadhesin chimeras. "Antigen-binding fragments" comprise a portion of a full-length antibody, preferably its variable domains, or at least its antigen-binding site ("antigen-binding fragments of antibodies"). Examples of antigen-binding fragments include Fab (antigen-binding fragment), scFv (single-chain variable fragment), single-domain antibodies (nanoantibodies), double antibodies, dsFv, Fab', double antibodies, single-chain antibody molecules, and multispecific antibodies formed by antibody fragments. Antibodies or antibody fragments can be human, fully human, humanized, human-engineered, non-human, and / or chimeric. Non-human antibodies or antibody fragments can be humanized to reduce immunogenicity to humans while retaining the specificity and affinity of the parent non-human antibody. A chimeric antibody may refer to an antibody created by joining two or more antibody genes that originally encoded separate antibodies.
[0141] The terms "specific", "specific binding" or "specific" for the antigen binding domains of antibodies, fragments thereof or CARs refer to antigen binding domains that recognize and bind to specific antigens, but do not substantially recognize or bind to other molecules in the sample. Antigen binding domains that specifically bind to antigens from one species can also bind to antigens from another species. This cross-species reactivity does not contradict the definition that the antigen binding domain is specific. The antigen binding domain that specifically binds to an antigen can also bind to different allelic forms of the antigen (allelic variants, splice variants, isotypes, etc.). This cross-reactivity does not contradict the definition that the antigen binding domain is specific.
[0142] The term "antigen" as used herein is intended to include substances that bind to or cause the production of one or more antibodies, and may include, but are not limited to, proteins, peptides, polypeptides, oligopeptides, lipids, carbohydrates such as dextran, haptens, and combinations thereof, such as glycosylated proteins or glycolipids. The term "antigen" as used herein refers to a molecular entity that can be expressed, for example, on the surface of a target cell and can be recognized by the adaptive immune system, including but not limited to antibodies or TCRs, or engineered molecules, including but not limited to endogenous or transgenic TCRs, CARs, scFvs or multimers thereof, Fab fragments or multimers thereof, antibodies or multimers thereof, single-chain antibodies or multimers thereof, or any other molecule that can bind to a structure with high affinity.
[0143] As used herein, the term "soluble antigen" refers to an antigen that is not immobilized on a surface (eg, a bead or a cell membrane).
[0144] The term "immune cell" or "immune effector cell" can be used interchangeably, and refers to cells that can be part of the immune system and perform specific effector functions, such as α-βT cells, NK cells, NKT cells, B cells, innate lymphocytes (ILC), cytokine-induced killer (CIK) cells, lymphokine-activated killer (LAK) cells, γ-δT cells, regulatory T cells (Treg), monocytes or macrophages. Preferably, these immune cells are human immune cells. Preferred immune cells are cells with cytotoxic effector functions, such as α-βT cells, NK cells, NKT cells, ILCs, CIK cells, LAK cells or γ-δT cells. The most preferred immune effector cells are T cells and NK cells. Tumor infiltrating lymphocytes (TIL) are T cells that have moved from the blood of a subject to a tumor. These TILs can be removed from a patient's tumor by methods well known in the art, such as enzymatic and mechanical tumor destruction, followed by density centrifugation and / or cell marker specific enrichment. As disclosed herein, TILs are genetically engineered and then returned to the patient. "Effector function" refers to a specialized function of a cell, for example in T cells, effector function may be cytolytic activity or helper activity, including the secretion of cytokines.
[0145] Immunotherapy is a medical term defined as "treating a disease by inducing, enhancing, or suppressing an immune response." Immunotherapy designed to elicit or amplify an immune response is classified as activating immunotherapy, while immunotherapy that reduces or suppresses it is classified as suppressing immunotherapy. Cancer immunotherapy, which is an activating immunotherapy, attempts to stimulate the immune system to reject and destroy tumors. Adoptive cell transfer uses a cell-based, preferably T-cell-based or NK-cell-based cytotoxic response to attack cancer cells. T cells with natural or genetically engineered reactivity to the patient's cancer are produced in vitro and then transferred back to the cancer patient. Immunotherapy is then referred to as "CAR cell immunotherapy" or, in the case of using only T cells, as "CAR T cell therapy" or "CAR T cell immunotherapy."
[0146] As used herein, the term "treating" means reducing the frequency or severity of at least one sign or symptom of a disease.
[0147] The term "autologous" as used herein refers to any material derived from the same subject into which it is subsequently reintroduced.
[0148] As used herein, the term "allogeneic" refers to any material derived from a different subject of the same species as the subject into which the material is reintroduced.
[0149] The term "therapeutically effective amount" or "therapeutically effective population" refers to the amount of a cell population that provides a therapeutic benefit in a subject.
[0150] The term "subject" as used herein refers to an animal. Preferably, the subject is a mammal, such as a mouse, rat, cow, pig, goat, chicken, dog, monkey or human. More preferably, the subject is a human. The subject can be a subject suffering from a disease such as cancer (patient) or an autoimmune disease or an allergic disease or an infectious disease or a transplant rejection.
[0151] The term "expression" as used herein is defined as the transcription of a specific nucleotide sequence into RNA and optionally the subsequent translation of the RNA into a polypeptide sequence or protein.
[0152] As used herein, the terms "engineered cells" and "genetically modified cells" are used interchangeably. The term refers to cells that contain and / or express exogenous genes or nucleic acid sequences, which in turn modify the genotype or phenotype of the cell or its progeny. In particular, the term refers to the fact that cells, preferably T cells, can be manipulated by recombinant methods well known in the art to stably or transiently express peptides or proteins that are not expressed in these cells in the natural state. For example, T cells (preferably human T cells) are engineered to express artificial constructs (e.g., chimeric antigen receptors) on their cell surface.
[0153] The term "cancer" is medically referred to as a malignant neoplasm. Cancer is a broad group of diseases involving unregulated cell growth and includes all kinds of leukemia. In cancer, cells (cancerous cells) divide and grow uncontrollably, forming malignant tumors and invading nearby parts of the body. Cancer can also spread to more distant parts of the body through the lymphatic system or bloodstream. There are more than 200 different known cancers that affect humans.
[0154] The terms "nucleic acid", "nucleic acid sequence" or "polynucleotide" as used interchangeably herein refer to polymers of nucleotides. Polynucleotides, which can be hydrolyzed into monomeric "nucleotides". Monomeric nucleotides can be hydrolyzed into nucleosides. The term "polynucleotide" as used herein encompasses, but is not limited to, all nucleic acid sequences obtainable by any means available in the art, including but not limited to recombinant means (i.e., cloning nucleic acid sequences from a recombinant library or cell genome using common cloning techniques and PCR, etc.), as well as by synthetic means.
[0155] The term "operably linked" refers to a functional connection between a regulatory sequence (e.g., a promoter) and a heterologous nucleic acid sequence that results in expression of the latter. For example, a first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Typically, operably linked DNA sequences are contiguous and, in the case of two protein coding regions that need to be linked, are in the same reading frame.
[0156] As used herein, the term "promoter" or "regulatory sequence" refers to a nucleic acid sequence required for transcription of a gene product (polynucleotide and / or polypeptide / protein) operably linked to a promoter / regulatory sequence. In some cases, the sequence may be a core promoter sequence, and in other cases, the sequence may also include an enhancer sequence and other regulatory elements required for transcription of a gene product. A promoter / regulatory sequence may be, for example, a sequence that expresses a gene product in a tissue-specific manner.
[0157] As used herein, term "minimal promoter" refers to the minimum genetic element that can induce the gene transcription located downstream of the minimal promoter. The eukaryotic promoter of a protein coding gene has one or more of three conserved sequences (i.e., TATA box, initiation region, and downstream promoter element) in this region. Minimal promoter enables low basal leakage to be achieved in the absence of specific transcription activators, and high expression is achieved when the transcription activator is combined in the upstream of the minimal promoter at its specific DNA binding site. Alternative minimal promoters can be used, such as minimal TATA box promoter, minimal CMV promoter, or minimal IL-2 promoter.
[0158] Minimal promoters can be engineered / modified by introducing binding sites for specific transcription factors (eg, required for drug-inducible systems).
[0159] A "constitutive" promoter is a nucleotide sequence that, when operably linked to a polynucleotide that encodes or specifies a gene product, results in production of the gene product in a cell under most or all physiological conditions of the cell.
[0160] An "inducible" promoter is a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, results in the production of a gene product in a cell substantially only in the presence or absence of certain conditions, such as when an inducer (e.g., an inducing signal, or an inducer such as a drug, metal ion, alcohol, oxygen, etc.) is present in the cell. A drug-inducible promoter is a promoter that can be regulated by the presence or absence of the drug that induces the promoter.
[0161] The constitutive promoter operably linked to the transgene (e.g., a synthetic transcription factor disclosed herein) can be, for example, the EF-1α promoter or any other constitutive promoter that drives constitutive expression in immune cells (e.g., MSCV, PGK-1, UBC, CMV, CAGG, SV40, or a pan-hematopoietic promoter such as vav).
[0162] Inducible promoters can include a minimal promoter (PMIN), such as the Elb minimal promoter. Alternative minimal promoters can be used, such as a minimal TATA box promoter, a minimal CMV promoter, or a minimal IL-2 promoter. In some embodiments, the minimal promoter can be optimized for a desired transcription level or rate.
[0163] In a particular variation, the inducible promoter may be a drug-inducible promoter.
[0164] Such systems can include nucleic acids comprising promoters inducible by drugs, such as promoters inducible by metabolites of synthetic drugs such as tamoxifen. By utilizing drug-inducible promoters, transgene expression can be turned on and off to avoid toxic side effects of the transgene and / or to allow cells to rest during remission. Many of these systems use chimeric transcriptional regulators (e.g., synthetic transcription factors).
[0165] In one variant, the inducible promoter can be induced by a drug, i.e., a drug-inducible promoter. The drug is selected according to a safety record, favorable pharmacokinetic characteristics, histological distribution, low partition coefficient between the extracellular space and the cytosol, low immunogenicity, low toxicity and / or high expression in lymphocytes. In some alternatives, the inducible promoter is activated by a transcriptional activator (e.g., a synthetic transcription factor) that interacts with the drug. The transcriptional activator is activated or can bind and activate the inducible promoter in the presence of the drug. The specific alternative of the drug is a drug combined with the estrogen receptor ligand binding domain of the transcriptional activator. In some alternatives, the drug includes tamoxifen, its metabolites, analogs, and pharmaceutically acceptable salts and / or hydrates or solvates thereof.
[0166] The term "synthetic transcription factor" as used herein may comprise a DNA binding domain, a ligand binding domain (drug-inducible domain or drug binding domain) and an activation (effector) domain, which are linked and / or fused, whereby the individual domains may be arranged in any order.
[0167] The DNA binding domain of the synthetic transcription factor can be a protein or part of a protein that specifically recognizes the DNA binding site of the drug-inducible promoter and mediates the binding of the synthetic transcription factor to the DNA sequence. In addition to zinc finger proteins, TALE (transcription activator-like effector) and Cas9 (clustered regulatory interspaced short palindromic repeats related system) can be engineered to recognize specific DNA sequences. In addition, the DNA binding domain of a naturally occurring transcription factor (e.g., a POU homology domain) can be used.
[0168] The DNA binding domain as disclosed herein may be a zinc finger protein.
[0169] The DNA binding site of a drug-inducible promoter (composed of a response element) is a specific DNA sequence that is directly or indirectly (in the case of Cas9) recognized by the DNA binding domain of a synthetic transcription factor. For example, each zinc finger domain specifically recognizes a 3bp DNA sequence (called a target site), so a three-finger zinc finger protein can be designed to recognize a 9bp sequence (called a recognition motif).
[0170] Cys2His2 zinc finger (ZF) protein is the most common DNA binding domain found in eukaryotes, and represents the second most commonly encoded protein domain in the human genome with about 700 Cys2His2 ZF encoding genes. In addition to the classical ZF Cys2His2 protein, at least two other classes of zinc coordination DNA binding proteins can be distinguished based on their structure and the way they coordinate zinc. Cys2Cys2 (or Cys4) ZF contains a conserved Zn binding consensus sequence of Cys-X2-Cys-X13-Cys-X2-Cys, and can be found primarily in nuclear steroid or hormone receptors (e.g., estrogen receptors). The second class is characterized by the Cys6-zinc cluster present in, for example, a metabolic regulator of fungi (e.g., yeast GAL4). Although the DNA binding mechanisms of all three classes of zinc coordination DNA binding proteins are well understood, it is mainly the Cys2His2 finger that is used to design polydactyl ZFPs with new and unique DNA specificity. The Cys2His2 ZF domain consists of approximately 30 amino acids and folds into a conserved left-handed ββα-secondary structure that is stabilized internally by hydrophobic interactions and chelation of zinc ions. The zinc atom is coordinated by a conserved cysteine within the β-sheet hairpin and a histidine within the α-helix. X-ray crystal structure analysis shows that one ZF domain typically recognizes 3 bp in the major groove of double-stranded DNA (called the target site). Therefore, the amino acids at positions -1, 3, and 6 relative to the start of the α-helix contact the 3', middle, and 5' nucleotides of the 3 bp subsite, respectively. In addition, α-helix position 2 mediates cross-chain interactions by recognizing bases on the reverse strand that are complementary to the nucleotide recognized by α-helix position 6 in the front finger. This cross-chain interaction synergistically connects the fingers into overlapping arrays. Proteins containing Cys2His2 ZF domains typically display different tandem repeats of the ZF domain. For example, the transcription factor Zif268 has three ZF domains that specifically recognize a 9 bp DNA sequence (called a recognition motif).
[0171] The ligand binding domain (or drug binding domain of a synthetic transcription factor) refers to a protein or portion of a protein that binds to a drug (ligand). Upon drug binding, the drug binding domain enables conversion from an inactive synthetic transcription factor to an active synthetic transcription factor. This conversion may include the release of an inactive factor and / or the translocation of a synthetic transcription factor from the cytoplasm to the nucleus. Examples of drug binding domains are activation sites of nuclear receptors, extracellular domains of receptors, antigen / substance binding proteins (also dimers) and / or enzymes.
[0172] The ligand binding domain (LBD) can be a modified human estrogen receptor as disclosed herein. The modified human estrogen receptor can include modifications that result in loss of responsiveness to natural ligands (i.e., estrogens) rather than to synthetic ligands (i.e., drugs, such as metabolites of tamoxifen, such as 4-hydroxytamoxifen or endoxifen).
[0173] The modified human estrogen receptor may comprise amino acid substitutions as disclosed herein (G400V, M543A, L544A or G400V, L540A, M543A or G400V / L539A / L540A).
[0174] The modified human estrogen receptor, wherein the modified human estrogen receptor may comprise SEQ ID NO: 10 or SEQ ID NO: 11 or SEQ ID NO: 12. Estrogen receptors (ER) are a group of proteins present in cells. They are receptors activated by the hormone estrogen (17β-estradiol). There are two types of ER: nuclear estrogen receptors (ERα and ERβ), which are members of the nuclear receptor family of intracellular receptors, and membrane estrogen receptors (MER) (GPER (GPR30), ER-X and Gq-mER), which are mainly G protein-coupled receptors.
[0175] The activation domain of a synthetic transcription factor refers to a protein or portion of a protein that spontaneously promotes the recruitment of the transcription machinery to initiate mRNA transcription. Examples of activation domains are fragments of VP16, VP64, NFκB p65, heat shock factor 1, and combinations thereof. The activation domain of a synthetic transcription factor as disclosed herein can be the p65 activation domain of human transcription factor NFκB or a functional variant thereof.
[0176] NF-κ-B (NKκB) is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are triggered by a large number of stimuli associated with many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-κ-B is a homodimer or heterodimer complex formed by the Rel-like domain-containing proteins RELA / p65, RELB, NFKB1 / p105, NFKB 1 / p50, REL and NFKB2 / p52. The heterodimer RELA-NFκB1 complex appears to be the most abundant one, in which the p65 subunit is responsible for the strong transcriptional activation potential of NF-κ-B.
[0177] The drug-inducible promoter may be a hybrid promoter comprising a binding site for a DNA binding domain (DBD) and a minimal promoter, the minimal promoter comprising a minimal promoter selected from the group consisting of Elb, TK, IL2, CMV, SV40.
[0178] The term "drug-inducible (gene) expression system" or "drug-induced (gene) expression system" refers to the expression of exogenous polynucleotides and / or polypeptides (transgenes) in human (immune) cells, generally herein. When a drug (e.g., a synthetic drug, such as a metabolite of tamoxifen) can be introduced into a cell, the inducible gene expression system can be activated in a cell having the inducible (gene) expression system. The drug in the cell can bind to a synthetic transcription factor, and can subsequently lead to the induction of the expression of the polypeptide and / or transgene.
[0179] Such drugs may also be referred to as "inducing agents".
[0180] Inducible expression systems drive the expression of exogenous polynucleotides and / or polypeptides in the presence of an inducing agent. In an induced system, withdrawal of the inducing agent can reduce and / or stop the expression of the exogenous polynucleotides and / or polypeptides. After reintroduction of the inducing agent, the system can then be reinduced and the expression of the exogenous polynucleotides and / or polypeptides can be restarted.
[0181] In some embodiments, the inducible (gene) expression system as disclosed herein can also provide adjustable control of the expression of polynucleotides and / or polypeptides. As used herein, the term "adjustable control" refers to the ability to control the expression level of polynucleotides and / or polypeptides as disclosed herein. For example, the level of induced expression of a transgenic can depend on the amount of the inducing signal present. For example, the presence of a higher amount of an inducer (e.g., a synthetic drug) can induce a higher level of transgenic expression compared to the presence of a lower amount of an inducer. Therefore, the inducible or adjustable expression of a polynucleotide and / or polypeptide can be dose-dependent relative to the amount of the inducer present.
[0182] In addition to the inducing agent drug dosage, in some embodiments, the inducible (gene) expression system as disclosed herein can also provide adjustable control of polynucleotide and / or polypeptide expression by the number of response elements for synthetic transcription factors. As used herein, the term "adjustable control" can refer to the ability to control the expression level of polynucleotides and / or polypeptides as disclosed herein. For example, the induced expression level of polynucleotides and / or polypeptides can depend on the number of response elements, in other words, the number of binding sites for synthetic transcription factors in inducible promoters. For example, after five synthetic transcription factor molecules are combined with an inducible promoter comprising five response elements, compared with a construct comprising two response elements in an inducible promoter, transcription output is induced, i.e., the expression of a higher level of polynucleotides and / or polypeptides. Therefore, the inducible or adjustable expression of polynucleotides and / or polypeptides can depend on the number of response elements of synthetic transcription factors.
[0183] A specific alternative to the drug is a drug that binds to the estrogen receptor ligand binding domain. In some alternatives, the drug includes tamoxifen, its metabolites, analogs, and pharmaceutically acceptable salts and / or hydrates or solvates thereof.
[0184] Tamoxifen, CAS RN 10540-29-1, is also known as 2-(4-((1Z)-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine, or (Z)-2-(p-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC), and has the molecular formula C26H29NO, MW 371.52. Tamoxifen is a selective estrogen receptor modulator with tissue-specific activity. Tamoxifen acts as an anti-estrogen (inhibitor) in breast tissue, but acts as an estrogen (stimulator) in cholesterol metabolism, bone density and endometrial cell proliferation. Tamoxifen is usually administered orally as a pharmaceutically acceptable salt.
[0185] Metabolites of tamoxifen are, for example, N-desmethyl tamoxifen (RN 31750-48-8, MW 357.494) and 4-hydroxy tamoxifen (4-OHT). Additional cytochrome P-450 metabolites are cis-4-hydroxy tamoxifen (RN 174592, MW 387.52; Afimoxifene, E-isomer) and 4'-hydroxy tamoxifen ((Z)-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-1-phenylbut-1-en-2-yl)phenol).
[0186] Compounds with similar structures to tamoxifen include, but are not limited to, cis-tamoxifen (RN 13002-65-8, MW 371.521), 4-methyl tamoxifen (RN 73717-95-5, MW 385.548), N-desmethyl tamoxifen (RN 31750-48-8, MW 357.494), (Z)-desethyl methyl tamoxifen (RN 15917-50-7, MW 357.494), (E)-desethyl methyl tamoxifen (RN 31750-45-5, MW 357.494), trans-4-hydroxy tamoxifen (RN 68047-06-3, MW 387.52), afexifen (RN 68392-35-8, MW 387.52), 4-hydroxy tamoxifen, E-isomer (RN 174592-47-3, MW387.52), 4-chlorotamoxifen (RN 77588-46-6, MW405.966), 4-flutamoxifen (RN 73617-96-6, MW389.511), toremifene (RN 89778-26-7, MW405.966), desethyltamoxifen (RN 19957-51-8, MW343.47), (E)-desethyltamoxifen (RN97151-10-5, MW343.47), (Z)-desethyltamoxifen (RN 97151-11-6, MW343.47), miproxifen (RN 129612-87-9, MW429.6), 2-(p-(β-ethyl α-phenylphenylphenyl(phenoxy)triethylamine (RN 749-86-0, MW399.575), droloxifene (RN 82413-20-5, MW387.52), 4-iodo-tamoxifen (RN 116057-68-2, MW497.413), dihydrotamoxifen (RN 109640-20-2, MW373.537), (E)-N,N-dimethyl-2-(4-(1-(2-methylphenyl)-2-phenyl-1-butenyl)phenoxy)ethylamine (RN 97150-96-4, MW385.548) or 4-hydroxytoremifene (RN 110503-62-3, MW421.965) and / or pharmaceutically acceptable salts and / or hydrates or solvates thereof.
[0187] The N-terminus (also called the amino terminus, NH2-terminus, N-terminal end or amine terminus) is the starting point of a protein or polypeptide and refers to the free amine group (-NH2) at the end of a polypeptide.
[0188] The C-terminus (also called the carboxyl terminus, carboxyl terminus, C-terminal tail, C-terminal end or COOH terminus) is the end of an amino acid chain (protein or polypeptide), terminated by a free carboxyl group (-COOH).
[0189] The kit may include a container with the components within it. Such a container may be, for example, a box, bottle, vial, tube, bag, pouch, blister pack, or other suitable container forms known in the art. Such a container may be made of plastic, glass, laminated paper, metal foil, or other materials suitable for holding the components therein. The kit may also include written instructions for using the kit components.
[0190] Implementation
[0191] In one embodiment of the present invention, immune cells such as T cells may comprise a system for tamoxifen or its derivatives such as 4-hydroxytamoxifen (4-OHT)-inducible expression of a chimeric antigen receptor (CAR) specific for an antigen on the surface of a cancer cell, the system may comprise
[0192] a) a first nucleic acid sequence comprising a first promoter inducible by tamoxifen or a derivative thereof (e.g., 4-OHT), wherein the first promoter may be operably linked to a polynucleotide encoding the CAR, wherein the first promoter may comprise a binding site for a DNA binding domain (DBD), wherein the binding site may comprise at least one response element recognized (bound) by the DNA binding domain (DBD), and
[0193] b) a second nucleic acid sequence comprising a second promoter, wherein the second promoter may be a constitutive promoter, wherein the second promoter may be operably linked to a nucleic acid sequence encoding a synthetic transcription factor, wherein the synthetic transcription factor may comprise
[0194] i) an activation domain (AD), wherein the AD may comprise the p65 activation domain of the human transcription factor NFκB
[0195] ii) a DNA binding domain (DBD), wherein the DNA binding domain (DBD) may be an N1 zinc finger protein (N1 ZFP)
[0196] iii) a ligand binding domain (LBD), wherein the LBD may be a modified human estrogen receptor, wherein the modified human estrogen receptor may comprise amino acid substitutions G400V, M543A, L544A compared to the amino acid sequence of a wild-type human estrogen receptor, wherein the ligand binding domain (LBD) is located at the C-terminus of the synthetic transcription factor.
[0197] The immune cell may express the CAR when contacted with tamoxifen or a derivative thereof, such as 4-OHT.
[0198] In one embodiment of the present invention, as disclosed herein, the immune cells expressing CAR inducible by tamoxifen or its derivatives (e.g., 4-OHT) are used to treat diseases associated with target cells of subjects suffering from the disease, and the disease may be, for example, cancer, and the target cells are cancerous cells. The immune cells of the subject, such as T cells or NK cells, can be separated. The subject may, for example, suffer from the cancer or may be a healthy subject. These cells can be genetically modified in vitro to express CAR when contacted with tamoxifen or its derivatives (e.g., 4-OHT) as disclosed herein. These engineered cells can be activated in vitro or in vivo using methods known in the art and expanded to a therapeutically effective amount. In cell therapy, these engineered cells can be infused into recipients in need thereof. These cells can be pharmaceutical compositions (the cells plus a pharmaceutically acceptable carrier). The infused cells may, for example, be able to kill cancerous cells in the recipient (or at least stop their growth). The recipient may be the same subject from which the cell is obtained (autologous cell therapy), or may be another subject from the same species (allogeneic cell therapy).
[0199] As disclosed herein, engineered immune cells, preferably T cells or NK cells, that can be inducibly expressed by tamoxifen or its derivatives (e.g., 4-OHT) can be administered alone, or as a pharmaceutical composition in combination with a diluent and / or with other components such as IL-2 or other cytokines or cell groups. In short, the pharmaceutical composition of the present invention may include a cell group of genetically modified cells (multiple immune cells) as described herein, and one or more pharmaceutically or physiologically acceptable carriers, diluents, or excipients. Such a composition may include a buffer, such as neutral buffered saline, phosphate buffered saline, etc.; carbohydrates such as glucose, mannose, sucrose or dextran, mannitol; protein; polypeptide or amino acid, such as glycine; antioxidant; chelating agent, such as EDTA or glutathione; adjuvant (e.g., aluminum hydroxide); and preservative.
[0200] Preferably, the compositions of the invention may be formulated for intravenous administration.Administration of the cell composition to a subject may be carried out in any convenient manner known in the art.
[0201] The pharmaceutical composition of the present invention can be used in a manner suitable for the disease to be treated. Appropriate dosage can be determined by clinical trials. However, the amount and frequency of use will also be determined and affected by factors such as the patient's condition and the type and severity of the patient's disease.
[0202] The pharmaceutical composition comprising immune cells (preferably T cells or NK cells) expressing an inducible expression system as disclosed herein can be administered at 10 4 Up to 10 9 cells / kg body weight, preferably 10 5 Up to 10 6 Cell compositions can be administered in amounts of 10 cells / kg body weight. Cell compositions can also be administered several times at these amounts. Cell compositions can be injected, for example, directly into tumors, lymph nodes, or infection sites.
[0203] In addition to the pharmaceutical composition comprising the genetically engineered immune cells, the inducer tamoxifen or its derivatives (such as 4-OHT) can also be applied to the subject intended to be treated. The inducer can be applied to the subject simultaneously with the immune cells, or can be applied subsequently, such as one day or one week later. The standard dose range of tamoxifen is 20-40mg per day, and can be given up to 5 years. The peak plasma concentration of tamoxifen can occur in about 5 to 7 hours after a single oral dose of 20mg, and the average concentration is 40ng / mL. Under the steady-state conditions obtained after daily administration for 80 days, tamoxifen can reach a plasma level of 71-183ng / mL. Tamoxifen is mainly metabolized extensively by the CYP enzymes in the liver. Therefore, metabolism follows two approaches, 4-hydroxylation and N-demethylation, to obtain 4-OHT and N-desmethyl tamoxifen (NDM-tamoxifen) respectively. Finally, two primary metabolites are converted into secondary metabolites, endoxifen.
[0204] A daily oral dose of 4 mg endoxifen should result in serum concentrations similar to those found in rapid metabolizers treated with standard tamoxifen (20 mg / day). Example
[0205] Example 1: Generation of drug-inducible CAR T cells
[0206] 1.1 Construct design
[0207] Inducible T cells constitutively express synthetic transcription factors via PGK promoter.Synthetic transcription factors are composed of 3 zinc finger proteins referred to as N1, the ligand binding domain of human estrogen receptor and the activation domain (in different directions of each domain) derived from NFκB p65.The sequence of synthetic transcription factors is connected to LNGFR used as a transduction marker via furin P2A site.Inducible gene expression cassette also includes sequences for anti-CD20 CAR, whereby the transcription of anti-CD20 CAR is regulated by inducible promoter.The second generation anti-CD20 CAR introduces the leader sequence from huGM-CSFR, anti-CD20 scFv, CD8 hinge and transmembrane domain based on Leu-16, and the cytoplasmic domain of 4-1BB and CD3ζ.Inducible promoter is composed of binding sites for N1 zinc fingers (five response elements) connected to Elb minimal promoter.
[0208] 1.2 Generation and titration of LV particles
[0209] Lentiviral vector particles are prepared via transient transfection of HEK-293T cells. Lentiviral vector particles are pseudotyped with VSV-G. For transfection, before transfection, HEK-293T cells are inoculated in T175 culture flasks supplemented with 2mM L-glutamine (Lonza) and 10% FCS (Biochrom) DMEM (Biowest) for 3 days. On the day of transfection, the culture medium is removed and replaced with DMEM (Biowest) supplemented with 2mM L-glutamine (Lonza). Cells are transfected with a three-plasmid system encoding VSV-G, gag / pol / rev and psi positive transfer vectors (anti-tag CAR or inducible cassettes). After 48h, the supernatant is collected and centrifuged at 1000rpm for 10min to remove cell debris. In addition, the supernatant is filtered through a 0.45 μm filter. The pellet is resuspended in ice-cold PBS and stored at -80 °C.
[0210] Functional titers of VSV-G pseudotyped lentiviral vector particles were determined via titration on Sup-Tl cells. 2E5 cells were seeded in 100 μL RPMI (Biowest) supplemented with 2mM L-glutamine (Lonza) in a 96-well round-bottom plate. For transduction, 100 μL of serially diluted lentiviral vector particles were added to the inoculated cells. After 24 h, 90 μL RPMI (Biowest) supplemented with 2mM L-glutamine (Lonza) and 10% FCS (Biochrom) were added. After 96 h, the frequency of transduced cells was quantified by flow cytometry using LNGFR APC conjugate (Miltenyi Biotec). Titers were calculated based on the frequency of LNGFR positive cells, the number of cells seeded, and the volume of lentiviral particles used for transduction. Titers are expressed in transduction units per mL.
[0211] 1.3 Transduction, culture, and analysis of inducible CAR T cells
[0212] Inducible CAR T cells are prepared using primary T cells from healthy donors. According to the manufacturer's protocol, T cells are isolated from PBMC using a PAN T cell isolation kit (Miltenyi Biotec). Before transduction, 2E6T cells are seeded in 24-well plates with 2mL TexMACS culture medium (Miltenyi Biotec) supplemented with IL-7 (Miltenyi Biotec), IL-15 (Miltenyi Biotec) and TransAct (Miltenyi Biotec). After 24h, T cells are transduced with an MOI of 5 by adding a corresponding volume of lentiviral vector particles. On the 3rd day after activation, the culture medium is removed and replaced with a TexMACS culture medium (Miltenyi Biotec) supplemented with IL-7 (Miltenyi Biotec) and IL-15 (Miltenyi Biotec). Using anti-LNGFR-APC conjugates (Miltenyi Biotec), LNGFR expression is determined by flow cytometry, and the frequency of inducible CAR T cells is indirectly analyzed on the 6th day after transduction. Transduced T cells were enriched for LNGFR positive cells on day 7 post-transduction using MACSelect LNGFR microbeads (Miltenyi Biotec). The enrichment procedure was performed according to the supplier's protocol. Functional assays were performed using transduced T cells on day 13 post-activation.
[0213] Example 2: Inducing anti-CD20 CAR expression in primary T cells
[0214] As described in Example 1.2, lentiviral particles encoding different drug-inducible boxes are manufactured. Drug-inducible T cells are produced as described in Example 1.3. 1E4 LNGFR positive drug-inducible T cells are inoculated in 100 μL TexMACS medium (Miltenyi Biotec) supplemented with IL-7 (Miltenyi Biotec) and IL-15 (Miltenyi Biotec) in 96 round-bottom well plates. Anti-CD20 CAR expression is induced by adding different concentrations of 4-OHT (0-250nM, Sigma-Aldrich) in 100 μL TexMACS medium (Miltenyi Biotec) supplemented with IL-7 (Miltenyi Biotec) and IL-15 (Miltenyi Biotec) to each well. Untransduced T cells constitute a negative control. T cells constitutively expressing anti-CD20CAR ("direct CAR") represent positive controls. Cells are cultured at 37 ° C and 5% CO2. T cells were analyzed by flow cytometry for anti-CD20 CAR expression 40h after induction using anti-CD20 CAR detection reagent-PE. Therefore, T cells were pelleted at 300g for 5min and stained with 50μL staining mixture consisting of anti-CD20 CAR detection reagent-PE and anti-LNGFR-APC diluted in CliniMACS buffer (Miltenyi Biotec) supplemented with 0.5% BSA (Miltenyi Biotec) (referred to as PEB). Staining was performed at 4°C for 10min, followed by two consecutive washing steps (300g, 5min) with 200μL PEB. The cells were resuspended in 100μL PEB for subsequent flow cytometry analysis. In order to exclude dead cells, Propidium iodide (PI; Miltenyi Biotec) was added to the stained cells directly before sample collection on the analyzer 10 (Miltenyi Biotec). + The frequency of inducible T cells (left panel) and the mean fluorescence intensity (MFI) of anti-CD20 CAR expression (right panel) were normalized to the expression of the transduction marker LNGFR.
[0215] Induction of anti-CD20 CAR expression by inducible T cells (both constructs) was strictly dependent on the presence of the inducer drug 4-OHT, with higher drug doses leading to greater induction ratios. At the same time, surface expression (expressed as MFI) increased steadily with drug dose.
[0216] Example 3: In the presence of GFP + CD20 +Cytotoxic activity of inducible anti-CD20 CAR T cells in co-cultures of Mel526
[0217] To evaluate tumor cell lysis mediated by inducible CAR T cells in real time, a live cell imaging-based killing assay was performed using the GFP+CD20+ tumor cell line 526-Mel. Therefore, 1E4 GFP+CD20+Mel526 cells were seeded in 50μL TexMACS medium (Miltenyi Biotec) in a 96-well flat-bottom plate. Subsequently, inducible CAR T cells were added at an E:T ratio of 1:1 in a volume of 100μL TexMACS medium (Miltenyi Biotec). The number of T cells was adjusted to LNGFR expression indicating that the number of transduced T cells and the total number of T cells in each well were equal. The number of untransduced T cells was adjusted to the total number of cells. At the beginning of the assay, anti-CD20 CAR expression was induced by adding 100nM4-OHT (Sigma-Aldrich) to 50μL TexMACS (Miltenyi Biotec). The plate was centrifuged at 300g for 1min and transferred to In device. The S3 device automatically and periodically acquires images of labeled tumor cells over time and correlates the fluorescent signal with tumor cell growth.
[0218] After an initial incubation period of about 20 hours, in the presence of 4-OHT, inducible anti-CD20 CAR T cells effectively lysed GFP+CD20+526-Mel cells. Between the two inducible constructs, the elimination rate was comparable and slightly delayed compared to the conventional constitutively expressed anti-CD20 CAR ("direct CAR"). The tumor-specific cytotoxicity of inducible CAR T cells is strictly dependent on the presence of 4-OHT, characterized in that there is no basal lysis in the non-induced state. In the untransduced control group, tumor cells maintained a stable growth phase throughout the experiment.
[0219] Example 4: In the presence of GFP + CD20 + Cytokine secretion by inducible anti-CD20 CAR T cells in co-cultures of Mel526
[0220] The ability of inducible anti-CD20 CART cells to secrete effector cytokines in co-culture with tumor cells was analyzed using the Human MACS Plex 12 Cytokine Kit (Miltenyi Biotec). + CD20 +Mel526 cells were seeded in 50 μL TexMACS medium (Miltenyi Biotec) in a 96-well flat-bottom plate. Subsequently, inducible CAR T cells were added in a volume of 100 μL TexMACS medium (Miltenyi Biotec) at an E:T ratio of 1: 1. The number of T cells was adjusted to indicate LNGFR expression equal to the number of transduced T cells and the total number of T cells in each well. The number of untransduced T cells was adjusted to the total number of cells. At the beginning of the assay, anti-CD20 CAR expression was induced by adding 100 nM 4-OHT (Sigma-Aldrich) to 50 μL TexMACS (Miltenyi Biotec). The plate was centrifuged at 300 g for 1 min and incubated at 37 ° C, 5% CO2 for 40 h. Then, 100 μL of the co-culture supernatant was transferred to a new 96-well plate and analyzed for cytokine levels using the Human MACS Plex 12 Cytokine Kit (Miltenyi Biotec) according to the manufacturer's instructions.
[0221] The secretion of human cytokines (hIFN-γ, left and hIL-2, right) by inducible anti-CD20 CAR T cells (both constructs) upon antigen engagement is strictly dependent on the presence of 4-OHT. In the non-induced state, cytokine levels in the supernatant were comparable to negative non-transduced controls. Induction of inducible anti-CD20 CAR T cells (both constructs) produced higher cytokine levels compared to CARs constitutively expressed under the control of the PGK promoter.
[0222] Example 5: Cytotoxic activity of inducible anti-CD20 CAR T cells in vivo
[0223] To study the in vivo functionality of inducible CAR T cells, the immunodeficient mouse strain NOD.Cg-PrkdcscidIL2rgtm1 Wjl / SzJ (NSG TM For tumor establishment, 4×10 5 Mouse-Adaptive Raji ffLuc Cells were injected iv into NSG TM The tumors were engrafted into the tail vein of mice. For individual mice, tumors were engrafted for 7 days, and tumor growth was monitored regularly by bioluminescence imaging and expressed as photon flux [photons / second] over time. Before T cell injection, mice were randomized based on BLI signal measured on day 0 to obtain equal distribution of tumor flux between treatment groups. Mice were treated with untransduced, inducible, or conventional constitutively expressing (“direct”) anti-CD20 CAR T cells. T cell numbers were adjusted to 3×106 LNGFR + T cells, ensuring equal numbers of transduced and total T cells per mouse. Adjust the number of untransduced T cells to the total number of cells injected into the CAR T cell group. Inject T cells in 100 μL PBS iv into NSG TM The tail vein of mice. Only the tumor control group (untreated) received 100 μL PBS injected iv. Tamoxifen (Sigma-Aldrich) was administered by ip injection at a dose of 1 mg every day. Therefore, tamoxifen was dispersed in 50 μL peanut oil (Sigma-Aldrich). The control group received only vehicle injection. Dosing began on day 0.
[0224] The rapid tumor outgrowth in the inducible anti-CD20 CAR group injected with vehicle was comparable to that of the untreated control group, confirming that there was no background anti-tumor efficacy in the non-induced state. In the presence of tamoxifen, inducible anti-CD20 CAR T cells with synthetic transcription factor orientation N1-p65-ER showed significant Raji cell lysis in 4 of 5 mice. However, compared with conventional control CAR, the elimination rate was slower. The second inducible anti-CD20 CAR T cell group with synthetic transcription factor orientation N1-ER-p65 reduced tumor growth in 2 of 4 mice in the presence of tamoxifen.
[0225] Example 6: Positioning of the activation domain within a synthetic transcription factor determines background expression in the non-induced state and transcriptional output
[0226] As described in Examples 1.2 and 1.3, T cells are transduced with synthetic transcription factors comprising zinc finger proteins (N1) of different arrangements, ligand binding domains of estrogen receptors (ER), and activation domains (p65). Inducible anti-CD20 CAR T cells comprising N1-ER-VP64 as synthetic transcription factors are used as controls. Assays are set and performed as described in Example 3. When cells are stained with anti-CD20 CAR detection reagent-PE and anti-LNGFR-APC, the frequency of anti-CD20 CAR+ inducible T cells (left figure) and the mean fluorescence intensity (MFI) (right figure) of anti-CD20 CAR+ inducible T cells are determined by flow cytometry analysis, and normalized to the expression of transduction marker LNGFR. For inducible CAR T cells comprising synthetic transcription factor constructs with ER at the C-terminal position, basal activity in a non-induced state was not detected. However, in the absence of inducer drugs, ER is positioned at the N-terminal end of the synthetic transcription factor to produce background expression. The induction ratio increases with the dose of inducer added to the T cell culture. At the same time, surface expression (expressed as MFI) increased steadily with drug dose. The maximum anti-CD20 CAR surface expression at the addition of 250nM 4-OHT was higher for synthetic transcription factor constructs with p65 (288-548) as the activation domain containing ER at the N-terminal position compared to the C-terminal position. The highest anti-CD20 CAR expression was detected for the control construct with the synthetic transcription factor N1-ER-VP64.
[0227] Example 7: Choice of activation domain within synthetic transcription factors determines background expression in the non-induced state and transcriptional output
[0228] As described in Examples 1.2 and 1.3, T cells were transduced with synthetic transcription factors comprising a zinc finger protein (N1), a ligand binding domain of the human estrogen receptor (ER), and different activation domains (NFκB p65 (aa361-551), NFκB p65 (aa288-548), or a fusion protein of NFκB p65 and HSF1 (heat shock factor 1). Inducible anti-CD20 CAR T cells containing N1-ER-VP64 as a synthetic transcription factor were used as a control. The assay was set up and performed as described in Example 3. Anti-CD20 CAR was determined by flow cytometry analysis when cells were stained with anti-CD20 CAR detection reagent-PE and anti-LNGFR-APC. + The frequency of inducible T cells (left panel) and the mean fluorescence intensity (MFI) of anti-CD20 CAR expression (right panel) were normalized to the expression of the transduction marker LNGFR.
[0229] If the synthetic transcription factor is composed of N1-p65(361-551)-ER, N1-p65(288-548)-ER or N1-ER-VP64, the anti-CD20 CAR expression induced by the inducible T cells is strictly dependent on the presence of the inducer drug. For those constructs, adding higher drug doses to T cell cultures produces a greater induction ratio. At the same time, surface expression (expressed as MFI) increases steadily with drug dose. The maximum anti-CD20 CAR surface expression is different between constructs, with N1-ER-VP64>N1-p65(361-551)-ER>N1-p65(288-548)-ER, showing increased levels. Interestingly, inducible T cells containing a hybrid activation domain composed of p65 and HSF1 arranged in the synthetic transcription factor N1-AD-ER show basal activity in a non-induced state.
[0230] sequence:
[0231] SEQ ID NO:1 (recognition sequence; amino acid sequence):
[0232] SQSSNLVR
[0233] SEQ ID NO:2 (recognition sequence; amino acid sequence):
[0234] SQSSSLVR
[0235] SEQ ID NO:3 (recognition sequence; amino acid sequence):
[0236] SRSDKLVR
[0237] SEQ ID NO:4 (Consensus zinc finger framework sequences derived from native and mutant forms of Sp1 zinc fingers; X = any natural amino acid):
[0238] MAQAALEPKEKPYACPECGKSFXXXXXXXXHQRTHTGEKPYKCP
[0239] ECGKSFXXXXXXXXHQRTHTGEKPYKCPECGKSFXXXXXXXXHQ
[0240] RTHTGKKTSGQAG
[0241] SEQ ID NO:5 (N1 zinc finger protein; amino acid sequence):
[0242] MAQAALEPKEKPYACPECGKSFSQSSNLVRHQRTHTGEKPYKCPE
[0243] CGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSRSDKLVRHQRT
[0244] HTGKKTSGQAG
[0245] SEQ ID NO:6 (Response element for N1; DNA sequence):
[0246] ggggtagaaaaaggggtagaa
[0247] SEQ ID NO:7 (Recognition motif for N1, n = a, c, g or t):
[0248] ggggtagaan SEQ ID NO:8 (p65 activation domain of human transcription factor NFkB; amino acid sequence): MDELFPLIFPAEPAQASGPYVEIIEQPKQRGMRFRYKCEGRSAGSIPGERSTDTTKTHPTIKINGYTGPGTVRISLVTKDPPHRPHPHELVGKDCRDGFYEAELCPDRCIHSFQNLGIQCVKKRDLEQAISQRIQTNNNPFQVPIEEQRGDYDLNAVRLCFQVTVRDPSGRPLRLPPVLSHPIFDNRAPNTAELKICRVNRNSGSCLGGDEIFLLCDKVQKEDIEVYFTGPGWEARGSFSQADVHRQVAIVFRTPPYADPSL QAPVRVSMQLRRPSDRELSEPMEFQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQA PAPVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLSQISS SEQ ID NO:9(Human ER aa282 to aa595; Amino Acid Sequence): SAGDMRAANLWPSPLMIKRSKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLLEMLDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV
[0249] SEQ ID NO:10 (Human ER (G400V, L540A, M543A); Amino Acid Sequence): MSAGDMRAANLWPSPLMIKRSKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPVKLLFAPNLLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLA QLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLALEALDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV SEQ ID NO:11(Human ER (G400V, M543A, L544A); Amino Acid Sequence): MSAGDMRAANLWPSPLMIKRSKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPVKLLFAPNLLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLLEAADAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV SEQ ID NO:12 (Human ER (G400V / L539A / L540A); Amino Acid Sequence): MSAGDMRAANLWPSPLMIKRSKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPVKLLFAPNLLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDAALEMLDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV.
Claims
1. A system for drug-inducible expression of a polynucleotide, comprising a) a first nucleic acid sequence comprising a first promoter inducible by the drug, wherein the first promoter is operably linked to the polynucleotide, wherein the first promoter comprises a binding site for a DNA binding domain, wherein the binding site comprises at least one response element recognized by the DNA binding domain (DBD), and b) a second nucleic acid sequence comprising a second promoter, wherein the second promoter is operably linked to a nucleic acid sequence encoding a synthetic transcription factor, wherein the synthetic transcription factor comprises i) an activation domain (AD), wherein the AD comprises the p65 activation domain of the human transcription factor NFκB, ii) the DNA binding domain (DBD), wherein the DBD comprises or consists of three zinc finger domains, iii) a ligand binding domain (LBD), wherein the LBD is a modified human estrogen receptor capable of binding the drug, and wherein the ligand binding domain (LBD) is located at the C-terminus of the synthetic transcription factor, c) the drug, wherein the drug is tamoxifen or a metabolite of tamoxifen.
2. The system according to claim 1, wherein the synthetic transcription factor comprises the AD, the DBD and the LBD from the N-terminus to the C-terminus, or wherein the synthetic transcription factor comprises the DBD, the AD and the LBD from the N-terminus to the C-terminus.
3. The system according to claim 1 or 2, wherein the DNA binding domain (DBD) is an N1 zinc finger protein (N1).
4. The system of any one of claims 1 to 3, wherein the modified human estrogen receptor comprises SEQ ID NO: 10 or SEQ ID NO: 11 or SEQ ID NO:
12.
5. The system of claim 1, wherein the metabolite of tamoxifen is 4-hydroxytamoxifen (4-OHT) or endoxifen.
6. The system according to any one of claims 1 to 5, wherein the polynucleotide encodes a therapeutically active protein.
7. The system of any one of claims 1 to 6, wherein the polynucleotide encodes a chimeric antigen receptor (CAR).
8. The system according to any one of claims 1 to 7, wherein the first nucleic acid sequence and the second nucleic acid sequence are located on one nucleic acid sequence of a vector.
9. A composition comprising A) Human immune cells, including a) a first nucleic acid sequence comprising a first promoter inducible by a drug, wherein the first promoter is operably linked to a polynucleotide, wherein the first promoter comprises a binding site for a DNA binding domain, wherein the binding site comprises at least one response element recognized by the DNA binding domain, and b) a second nucleic acid sequence comprising a second promoter, wherein the second promoter is operably linked to a nucleic acid sequence encoding a synthetic transcription factor, wherein the synthetic transcription factor comprises i) an activation domain (AD), wherein the AD comprises the p65 activation domain of the human transcription factor NFκB, ii) the DNA binding domain (DBD), wherein the DBD comprises or consists of three zinc finger domains, iii) a ligand binding domain (LBD), wherein the LBD is a modified human estrogen receptor capable of binding the drug, and wherein the ligand binding domain (LBD) is located at the C-terminus of the synthetic transcription factor, B) the drug, wherein the drug is tamoxifen or a metabolite of tamoxifen.
10. The composition of claim 9, wherein the human immune cell is a T cell or a NK cell, and wherein the polynucleotide encodes a chimeric antigen receptor.
11. A composition for treating a disease, comprising A) Human immune cells, including a) a first nucleic acid sequence comprising a first promoter inducible by a drug, wherein the first promoter is operably linked to a polynucleotide, wherein the first promoter comprises a binding site for a DNA binding domain (DBD), wherein the binding site comprises at least one response element recognized by the DNA binding domain, and b) a second nucleic acid sequence comprising a second promoter, wherein the second promoter is operably linked to a nucleic acid sequence encoding a synthetic transcription factor, wherein the synthetic transcription factor comprises i) an activation domain (AD), wherein the AD comprises the p65 activation domain of the human transcription factor NFκB, ii) the DNA binding domain (DBD), wherein the DBD comprises or consists of three zinc finger domains, iii) a ligand binding domain (LBD), wherein the LBD is a mutant human estrogen receptor capable of binding to the drug, and wherein the ligand binding domain (LBD) is located at the C-terminus of the synthetic transcription factor, B) the drug, wherein the drug is tamoxifen or a metabolite of tamoxifen.
12. The composition of claim 11, wherein the disease is cancer, wherein the human immune cell is a T cell or a NK cell, and wherein the polynucleotide encodes a chimeric antigen receptor specific for a tumor associated antigen (TAA) or a tumor specific antigen (TSA) expressed on cancerous cells of the cancer, and wherein the drug is 4-hydroxytamoxifen (4-OHT) or endoxifen.
